CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2371-2382

  Wang, Long ^a   Fan, Jie ^a   Thompson, Linda F ^b   Zhang, Yi ^c   Shin, Tahiro ^a   Curiel, Tyler J ^a   Zhang, Bin ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 ANILINOADENOSINE; 5' NUCLEOTIDASE; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; CD73 INHIBITOR; ENZYME INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD73; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL HOMING; CELL LINE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; EFFECTOR CELL; ENZYME ACTIVITY; GROWTH INHIBITION; HEMATOPOIETIC CELL; HOST; IMMUNOGENICITY; LYMPHOMA; MELANOMA; MOUSE; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE DIPHOSPHATE; ANIMALS; CHEMOTAXIS, LEUKOCYTE; DISEASE PROGRESSION; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, NON-HODGKIN; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RADIATION CHIMERA; SECOND MESSENGER SYSTEMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 79957921286     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45559     Document Type: Article

References (56)

1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263-274. (Pubitemid 40488632)
2. Schreiber H, ed. Tumor Immunology. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 2003:1557-1592.
3. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296. (Pubitemid 46697910)
4. Ohta A, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006;103(35):13132-13137. (Pubitemid 44338928)
5. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57(13):2602-2605. (Pubitemid 27283766)
6. Spychala J. Tumor-promoting functions of adenosine. Pharmacol Ther. 2000;87(2-3):161-173.
7. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010; 29(39):5346-5358.
8. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol. 2008;32(3):527-535. (Pubitemid 351330458)
9. Zhang B. CD73: A novel target for cancer immunotherapy. Cancer Res. 2010;70(16):6407-6411.
10. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.
11. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal. 2006;2(2):351-360.
12. Jin D, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010; 70(6):2245-2255.
13. Stagg J, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(4):1547-1552.
14. Yamashita Y, et al. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur J Immunol. 1998;28(10):2981-2990. (Pubitemid 28470244)
15. Airas L, Salmi M, Jalkanen S. Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J Immunol. 1993;151(8):4228-4238. (Pubitemid 23298756)
16. Strohmeier GR, et al. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest. 1997;99(11):2588-2601. (Pubitemid 27259805)
17. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol. 2006; 177(10):6780-6786. (Pubitemid 44715042)
18. Deaglio S, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265. (Pubitemid 46919862)
19. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008;118(4):1398-1404. (Pubitemid 351500433)
20. Takedachi M, et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol. 2008;180(9):6288-6296.
21. Alam MS, et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis. 2009;199(4):494-504.
22. Kline J, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008;14(10):3156-3167.
23. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192-3201. (Pubitemid 350106311)
24. Thomson LF, et al. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). Tissue Antigens. 1990;35(1):9-19. (Pubitemid 20044689)
25. Airas L, Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood. 1996; 88(5):1755-1764. (Pubitemid 26307072)
26. Novitskiy SV, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112(5):1822-1831.
27. Wilson JM, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol. 2009;182(8):4616-4623.
28. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 2010;11(11):1030-1038.
29. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol. 2005;5(10):760-771. (Pubitemid 41400850)
30. Airas L, et al. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte- vascular adhesion protein 2 identifies it as CD73. J Exp Med. 1995;182(5):1603-1608.
31. Airas L, Niemela J, Jalkanen S. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J Immunol. 2000;165(10):5411-5417.
32. Thompson LF, et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200(11):1395-1405. (Pubitemid 39657287)
33. Eltzschig HK, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104(13):3986-3992. (Pubitemid 39620148)
34. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood. 2008;111(4):2024-2035. (Pubitemid 351451513)
35. Mills JH, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105(27):9325-9330.
36. Koszalka P, et al. Targeted disruption of cd73/ecto- 5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95(8):814-821. (Pubitemid 39390584)
37. Chadjichristos CE, et al. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010;121(1):123-131.
38. Hasegawa T, Bouis D, Liao H, Visovatti SH, Pinsky DJ. Ecto-5' nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res. 2008;103(12):1410-1421.
39. Zernecke A, et al. CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. Circulation. 2006;113(17):2120-2127.
40. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil- derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188(8):1433-1443. (Pubitemid 28489580)
41. Stelzner TJ, Weil JV, O'Brien RF. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol. 1989;139(1):157-166. (Pubitemid 19120283)
42. Hansen KR, Resta R, Webb CF, Thompson LF. Isolation and characterization of the promoter of the human 5'-nucleotidase (CD73)-encoding gene. Gene. 1995;167(1-2):307-312.
43. Narravula S, Lennon PF, Mueller BU, Colgan SP. Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol. 2000;165(9):5262-5268.
44. Airas L, Niemela J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol- linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol. 1997;136(2):421-431. (Pubitemid 27063091)
45. Jackson SW, et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1- null mice. Am J Pathol. 2007;171(4):1395-1404. (Pubitemid 47582911)
46. Bynoe MS, Viret C. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol. 2008;29(3):99-102.
47. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993-1998.
48. Sun X, et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology. 2010;139(3):1030-1040.
49. Hilchey SP, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine- mediated T cell hyporesponsiveness. J Immunol. 2009;183(10):6157-6166.
50. Mandapathil M, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res. 2009;15(20):6348-6357.
51. Mandapathil M, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem. 2010;285(10):7176-7186.
52. Kryczek I, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141-1149.
53. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248-256.
54. Ryzhov S, et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia. 2008; 10(9):987-995.
55. Buckanovich RJ, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28-36.
56. Lin PY, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol. 2010;185(5):2747-2753.